BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34054047)

  • 21. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
    Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
    Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Treatment of Activated PI3Kδ Syndrome.
    Coulter TI; Cant AJ
    Front Immunol; 2018; 9():2043. PubMed ID: 30245694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
    Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
    J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
    Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
    Front Immunol; 2018; 9():568. PubMed ID: 29675019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
    Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
    Tang WJ; Wang W; Luo Y; Wang YP; Li L; An YF; Gou LJ; Ma MS; He TY; Yang J; Zhao XD; Song HM
    Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):19-24. PubMed ID: 28072954
    [No Abstract]   [Full Text] [Related]  

  • 27. APDS2 and SHORT Syndrome in a Teenager with PIK3R1 Pathogenic Variant.
    Ramirez L; Tamayo W; Ale H
    J Clin Immunol; 2020 Oct; 40(7):1020-1025. PubMed ID: 32778990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.
    Thouenon R; Moreno-Corona N; Poggi L; Durandy A; Kracker S
    Front Pediatr; 2021; 9():652405. PubMed ID: 34249806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
    Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
    Front Immunol; 2018; 9():1758. PubMed ID: 30116245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan.
    Moriya K; Mitsui-Sekinaka K; Sekinaka Y; Endo A; Kanegane H; Morio T; Imai K; Nonoyama S
    Immunol Med; 2023 Dec; 46(4):153-157. PubMed ID: 37178059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An updated review on activated PI3 kinase delta syndrome (APDS).
    Singh A; Joshi V; Jindal AK; Mathew B; Rawat A
    Genes Dis; 2020 Mar; 7(1):67-74. PubMed ID: 32181277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
    Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
    J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
    Thauland TJ; Pellerin L; Ohgami RS; Bacchetta R; Butte MJ
    Front Immunol; 2019; 10():753. PubMed ID: 31031754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
    Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
    Front Immunol; 2019; 10():77. PubMed ID: 30891027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.
    Oh J; Garabedian E; Fuleihan R; Cunningham-Rundles C
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4095-4102. PubMed ID: 34352450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion.
    Pham MN; Cunningham-Rundles C
    Front Pediatr; 2018; 6():402. PubMed ID: 30619796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exhaustion of the CD8
    Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
    Front Immunol; 2018; 9():446. PubMed ID: 29563914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.
    Ewertowska M; Grześk E; Urbańczyk A; Dąbrowska A; Bąbol-Pokora K; Łęcka M; Kołtan S
    Allergy Asthma Clin Immunol; 2020; 16():22. PubMed ID: 32265996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.